<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459807</url>
  </required_header>
  <id_info>
    <org_study_id>TBD123</org_study_id>
    <nct_id>NCT03459807</nct_id>
  </id_info>
  <brief_title>Blood Pressure Lowering in Dialysis (BOLD) Trial</brief_title>
  <acronym>BOLD</acronym>
  <official_title>BOLD: A Trial of Blood Pressure Lowering in Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood pressure may be one of the most important modifiable risk factors for cardiovascular
      disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis.
      Although a systolic blood pressure &lt;140 mmHg treatment target has been recommended, there
      remains uncertainty on which blood pressure should be targeted, more specifically that
      measured in the dialysis unit or at home. Observational studies have reported a paradoxical
      U-shaped associated with dialysis unit (pre-dialysis) systolic blood pressure and
      cardiovascular events and death (where blood pressure below 140 mmHg is actually linked with
      poor outcomes). Conversely, the same studies have reported a linear association between
      higher home systolic blood pressure and worse clinical outcomes, where blood pressure below
      140 mmHg is associated with better outcomes. This pilot clinical trial aims to address this
      important question.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood Pressure Lowering in Dialysis (BOLD) is a pilot randomized controlled trial of 50
      maintenance hemodialysis patients in San Francisco and Seattle to test whether targeting a
      home systolic blood pressure &lt;140 mmHg (versus a pre-dialysis systolic blood pressure &lt;140
      mmHg) is feasible and safe. The study duration is 4 months and blood pressure targets will be
      achieved through dry weight adjustment and adjustment of standard anti-hypertensive therapies
      by the study team. The primary outcomes are focused on feasibility and safety. The home blood
      pressure treatment arm will also have the opportunity to utilize a blood pressure monitor
      with Bluetooth capabilities. The rates of utilization of mobile health technology in this
      population will also be assessed as an outcome. This pilot trial will provide key data to
      design a larger trial focused on clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility - screen:enrollment ratio</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage of eligible participants screened and eventually enrolled in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to assigned treatment arm</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage of participants in the home blood pressure (BP) arm who are able to measure home BP and transmit readings to the research team
Percentage of participants who drop out</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Assessed every 2 weeks over 4 months</time_frame>
    <description>Dialysis unit systolic BP &lt;90 mmHg
Dialysis unit systolic BP &gt;200 mmHg
Cramping during dialysis
Syncope episodes
Episodes of fall
Episodes of flash pulmonary edema
Symptoms of dizziness/lightheadedness/fatigue
Duration (in minutes) of recovery from dialysis treatments</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Blood Pressure</condition>
  <condition>End Stage Renal Disease on Dialysis (Diagnosis)</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Chronic Kidney Disease Stage 5</condition>
  <arm_group>
    <arm_group_label>Home systolic blood pressure (SBP) &lt;140 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.
Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.
Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-dialysis SBP &lt;140 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.
Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Hypertensive medications</intervention_name>
    <description>Use of standard Anti-Hypertensive medications</description>
    <arm_group_label>Home systolic blood pressure (SBP) &lt;140 mmHg</arm_group_label>
    <arm_group_label>Pre-dialysis SBP &lt;140 mmHg</arm_group_label>
    <other_name>anti-hypertensive</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dry Weight Adjustment</intervention_name>
    <description>The participant's target post-dialysis dry weight is adjusted</description>
    <arm_group_label>Home systolic blood pressure (SBP) &lt;140 mmHg</arm_group_label>
    <arm_group_label>Pre-dialysis SBP &lt;140 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Undergoing in-center, thrice weekly hemodialysis for treatment of
             end-stage-renal-disease

          3. Greater than 3 months since initiation of dialysis

          4. Age 18 years or above

          5. Able to obtain a brachial blood pressure at dialysis and at home

        Exclusion Criteria:

          1. Pregnancy, anticipated pregnancy, or breastfeeding as this will require increase to
             more than three time a week dialysis and/or preclude use of some classes of blood
             pressure medications

          2. Incarceration or institutionalized living which may prohibit measurement of home blood
             pressure

          3. Participation in another intervention study that may affect blood pressure

          4. Patients in whom systolic blood pressure is not measurable (e.g. those with left
             ventricular assist devices)

          5. Hypotension: average pre-dialysis systolic blood pressure &lt;100 mmHg over last 2 weeks
             prior to screening while not taking any blood pressure medications

          6. Life expectancy &lt;4 months

          7. Anticipated living donor kidney transplant within 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi-yuan Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nisha Bansal, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi-yuan Hsu, MD</last_name>
    <phone>415-353-2379</phone>
    <email>chi-yuan.hsu@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farshad Palad</last_name>
    <email>farshad.palad@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-yuan Hsu, MD</last_name>
      <phone>415-353-2379</phone>
      <email>chi-yuan.hsu@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Farshad Palad</last_name>
      <email>farshad.palad@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chi-yuan Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisha Bansal, MD, MAS</last_name>
      <phone>206-221-1801</phone>
      <email>nbansal@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori Linke</last_name>
      <phone>2067203835</phone>
      <email>LLinke@nephrology.washington.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. Erratum in: Lancet. 2003 Mar 22;361(9362):1060.</citation>
    <PMID>12493255</PMID>
  </reference>
  <reference>
    <citation>Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, MacMahon S. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation. 1995 Nov 1;92(9):2437-45.</citation>
    <PMID>7586343</PMID>
  </reference>
  <reference>
    <citation>MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765-74.</citation>
    <PMID>1969518</PMID>
  </reference>
  <reference>
    <citation>Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ. 2012 Aug 30;345:e5567. doi: 10.1136/bmj.e5567.</citation>
    <PMID>22936794</PMID>
  </reference>
  <reference>
    <citation>James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. Erratum in: JAMA. 2014 May 7;311(17):1809.</citation>
    <PMID>24352797</PMID>
  </reference>
  <reference>
    <citation>SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506.</citation>
    <PMID>26551272</PMID>
  </reference>
  <reference>
    <citation>Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003 Nov;42(5):1050-65. Review.</citation>
    <PMID>14604997</PMID>
  </reference>
  <reference>
    <citation>Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S16-23. Review.</citation>
    <PMID>11443763</PMID>
  </reference>
  <reference>
    <citation>Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol. 2001 Nov;12(11):2411-7.</citation>
    <PMID>11675417</PMID>
  </reference>
  <reference>
    <citation>Ok E, Asci G, Chazot C, Ozkahya M, Mees EJ. Controversies and problems of volume control and hypertension in haemodialysis. Lancet. 2016 Jul 16;388(10041):285-93. doi: 10.1016/S0140-6736(16)30389-0. Epub 2016 May 22. Review.</citation>
    <PMID>27226131</PMID>
  </reference>
  <reference>
    <citation>Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003 Mar;63(3):793-808. Review.</citation>
    <PMID>12631061</PMID>
  </reference>
  <reference>
    <citation>Duranti E, Imperiali P, Sasdelli M. Is hypertension a mortality risk factor in dialysis? Kidney Int Suppl. 1996 Jun;55:S173-4.</citation>
    <PMID>8743547</PMID>
  </reference>
  <reference>
    <citation>Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P. &quot;U&quot; curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998 Aug;54(2):561-9. Erratum in: Kidney Int 1998 Oct;54(4):1417.</citation>
    <PMID>9690224</PMID>
  </reference>
  <reference>
    <citation>Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000 Jul;58(1):353-62.</citation>
    <PMID>10886582</PMID>
  </reference>
  <reference>
    <citation>Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010 Mar;55(3):762-8. doi: 10.1161/HYPERTENSIONAHA.109.144899. Epub 2010 Jan 18.</citation>
    <PMID>20083728</PMID>
  </reference>
  <reference>
    <citation>Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med. 2013 Aug 20;159(4):233-42. doi: 10.7326/0003-4819-159-4-201308200-00004.</citation>
    <PMID>24026256</PMID>
  </reference>
  <reference>
    <citation>Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2012 Sep;82(5):570-80. doi: 10.1038/ki.2012.136. Epub 2012 Jun 20.</citation>
    <PMID>22718187</PMID>
  </reference>
  <reference>
    <citation>Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999 Mar;33(3):507-17.</citation>
    <PMID>10070915</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>End-stage-renal-disease</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

